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Abstract
Background Local tumour destruction has been shown to
give rise to changes in immunocompetent cells. The aim of
this study was to describe the effect of interstitial laser
thermotherapy (ILT) of breast carcinoma in the tumour and
in regional lymph nodes.
Methods Seventeen women that underwent radical sur-
gical excision after non-radical ILT were studied. ILT was
performed at a steady-state temperature of 48C for
30 min. Surgical excision was performed 12 (6–23) days
after ILT. Six patients with breast cancer not treated with
ILT before surgery served as controls. Immunohistological
reactions were performed on core needle biopsies prior to
treatment and on the excised specimens.
Results ILT resulted in more CD8 lymphocytes and
CD68 macrophages within the tumour (P\0.05 and
P\0.01, respectively) and higher counts of CD20
(P\0.05), CD68 (P\0.001) and CD83 (P\0.01) at the
tumour border, when compared to pre-treatment values. In
the control patients not receiving ILT, CD8 cells increased
within the tumour after resection (P\0.05). With the
probable exception of CD25 Foxp3 cells, the presence of
cancer in a lymph node inﬂuenced the ﬁndings in lymph
nodes (examined for CD1a, CD25, Foxp3 CD25, CD83
cells). Thus, comparisons between ILT and control patients
were restricted to patients without lymph node metastases.
In these patients, ILT and resection were followed by a
decrease in CD25 Foxp3 lymphocytes (P\0.05), when
compared to surgical resection alone.
Conclusions ILT induced changes in immunocompetent
cells in patients with breast cancer. The stimulation of the
immune system is an added feature of ILT in treatment of
patients with breast cancer.
Keywords Breast cancer  Laser thermotherapy 
Minimally invasive treatment  Tumour immunology
Introduction
Local minimally invasive methods have been evaluated for
the treatment of tumours, and promising results have been
published [1–5]. In breast cancer, surgery is still the stan-
dard treatment but improved diagnostic methods increase
the possibilities for local destruction methods such as
radiofrequency ablation, laser thermotherapy, cryotherapy
and high-intensity focused ultrasound [6–12]. Advantages
with these methods include minimal trauma, less immu-
nosuppression than standard surgical resection and possibly
the induction of a favourable immune response. Thus, the
above-mentioned local therapies have been shown to be
associated with changes in immunocompetent cells, pro-
viding indirect evidence that clinically important changes
in the immune response may be obtained [3–5, 10, 11].
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local destruction method since it gives precise control of
the lesion size and, most importantly, provides a unique
source of tumour antigens for the induction of anti-tumour
immunity. ILT keeps the temperature in the range of
46–50C at the tumour border, which causes tumour
necrosis at the same time as the temperature is below the
threshold for coagulation of proteins and thus tumour
antigens. The necrosis develops within a time range of
hours to a few days [13, 14] during which time uncoagu-
lated and undestroyed tumour antigens can be exposed to
the immune system. Furthermore, at this temperature level,
tumour blood ﬂow is not abolished [15].
In a rat liver tumour model, we have demonstrated
that ILT (a) is superior to surgical resection, (b) gives a
strong rejection immunity associated with an immune
cellular response of tumour-inﬁltrating macrophages and
CD8? lymphocytes, (c) results in pronounced suppres-
sion of the growth of a simultaneous untreated tumour
(distant bystander effect), (d) produces an increased anti-
tumour lymphocyte proliferative response in tumour-
draining and systemic lymph nodes and spleen and
(e) results in increased HSP70 immunoreactivity in
tumours and tumour-inﬁltrating macrophages [16–20].
Isbert et al. conﬁrmed some of these ﬁndings showing
an enhanced cellular immune response and a distant
bystander effect after laser-induced thermotherapy [21].
To summarize, experimental studies have shown that
laser-induced thermotherapy can induce immunity that
eradicates minimal residual disease and prevents metastatic
spread [20–22]. In the clinical situation, we have shown a
distant bystander effect after laser thermotherapy in a
patient with malignant melanoma [20].
The aim of this study was to ﬁnd out if ILT of breast
carcinoma induces changes in relevant immunocompetent
cells (B cells, several T cells, dendritic cells, macrophages)
in the tumour and in regional lymph nodes.
Materials and methods
Patients
In a previous study, we reported on 24 patients treated with
ILT under local anaesthesia. The characteristics and work-
up of these patients were described in detail in a previous
paper [7]. Seventeen of these patients had a 1–98% tumour
necrosis (mean 29%) on pathological examination and are
included in this study. Explanations for the wide range of
tumour necrosis included the inclusion of some relatively
large tumours and underestimation of tumour size by
mammography and ultrasound [7].
Main clinical characteristics in this study are sum-
marized in Table 1. None of the patients was taking
steroids, cytostatics or other immune suppressive drugs.
The patients’ age range was 39–73 (mean 57). The
diagnosis was invasive ductal carcinoma in nine patients,
a lobular carcinoma in 7 and lobular ductal cancer in 1.
Average tumour diameter was 13 mm on ultrasound
(5.3–35). Seven of the ILT patients, and one of the
control patients, had axillary lymph node metastases
(Table 1).
Treatment was carried out with a system consisting of
a 805-nm diode laser (Diomed 25, Diomed, Cambridge,
UK) and a temperature feedback control unit interfaced
with the laser, as described previously [7]. A 600 lm
diameter ﬂexible bare ﬁbre housed in a polyvinyl sheet
(D-6065, Diomed) was used to deliver the laser light
interstitially. The temperature feedback control unit
consisted of a personal computer, an automatic thermom-
etry system (ATS-100, Lund Science, Lund, Sweden) and a
thermistor probe (Aditus Medical Science AB, Lund,
Sweden) inserted into a steel cannula (outer diameter
0.8 mm). An optical beam splitter (Diomed) was used,
when the treatment was performed with more than one ﬁbre.
Treatment was performed at a steady-state target tempera-
ture of 48C for 30 min, and the output laser power (max-
imum power was 3 W per ﬁbre) was stepwise regulated to
keep the treatment temperature stable.
Six patients, aged 43–76 (mean 59) years, receiving
surgical resection only served as controls.
They were all considered for ILT but this was not per-
formed because we could not accurately deﬁne the tumour
border with pre-treatment ultrasound. One of these patients
had invasive lobular cancer and ﬁve had invasive ductal
cancer. Tumour size was 9–19 mm (mean 13 mm).
Table 1 Clinical characteristics
ILT patients
(n = 17)
Control patients
(n = 6)
Tumour size, mm
Ultrasound 13 (5.3–35) 11 (8–14)
Microscopic 20 (7–55) 13 (9–19)
Pathological diagnosis D/L/LD
a 9/7/1 5/1/0
Tumour necrosis, % 29 (1–98) –
Lymph node metastases, Y/N 7/10 1/5
ER/PR
a 15/12 4/5
Histological grading I/II/III
b 3/12/2 3/3/0
D ductal carcinoma, L lobular carcinoma, LD lobular ductal
carcinoma
a Two ILT and one control patient were negative for both ER and PR
b The two ILT patients who were negative for both ER and PR had
grade II and III
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123The study was approved by the local ethics committee
and informed verbal and written consent was obtained in
all patients.
Pathological examination
After palpation of the resected specimen, a section was
cut through the middle of the tumour. Sections of
5–10 mm were cut from the fascia through the whole
specimen perpendicular to and down to the skin. Tumour
size and resection margins were noted and measured.
The slices, still adherent to the skin, were ﬁxed in 6%
formaldehyde for 24–72 h. Core biopsies, with 18 or 16
gauge needles, and lymph nodes were also ﬁxed for
24–72 h. The large slices were embedded in parafﬁn and
cut, due to thickness, on one or two levels and stained
with haematoxylin-eosin.
Immunohistological methods
All immunohistological reactions were performed on par-
afﬁn-ﬁxed sections. From the large blocks of resected
cancer, vital tumour areas with a few mm of surrounding
tissue, slightly more than 1 9 1 cm, were chosen. The
entire needle biopsies and sections from the lymph nodes
were also used.
For single immunohistochemistry, the reactions were
performed in an automatic immunostainer TechMate 500
(Ventana BioTech Systems, Tucson, AZ, USA) with Dako
ChemMate Detection kit peroxidase/DAB?, giving a
brown colour (Dako A/S, Glostrup, Denmark). They were
performed with antibodies against CD1a, an antigen char-
acterizing one type of immature dendritic cells (diluted
1:50, Dako, Glostrup, Denmark), CD4, a T helper cell
antigen (1:100, Novocastra, Newcastle, UK), CD8, a
T cytotoxic cell antigen (1:20, Dako), CD20, a B cell
antigen (1:2,000, Dako), CD25, the interleukin-2 receptor
(1:100, Novocastra), CD57, an NK cell antigen (1:100,
Novocastra), CD68, a macrophage antigen (1:20, Dako),
CD83, a mature dendritic cell antigen (1:20, Novocastra),
CD94, an NK cell antigen (1:20, Immunotech, Marseille,
France), granzyme B, an antigen for perforin and granzyme
B present in some cytotoxic T cells and NK cells (1:50,
Dako), Foxp3, an antigen for forkhead/winged helix family
of transcription factors (1:100, 236A/E7, eBioscience, San
Diego, USA). The antibody against the oestrogen receptor
alfa was Dako clone 1D5 (diluted 1:35) and against the
progesterone receptor Dako clone PgR 636 (1:150). For
these two antibodies, the Dako DAB kit K5001 was used.
The background staining was done with Mayer’s
haematoxylin.
Double staining immunohistochemical reactions were
performed for CD25? Foxp3?. The double staining was
made in DakoCytomation Autostainer (Dako, Glostrup,
Denmark). We used Envision G/2 Doublestain System
(1:100 for both antibodies, Dako code K5361) where DAB,
brown colour was used for Foxp3 and permanent red was
used for CD25.
Tissue analysis
Photos of the immunohistological reactions were taken of
vital tumour at the tumour border and in the interior of
the cancers using a standard light microscope and a 109
objective (Bx-60, Olympus, Tokyo, Japan). The tumour
border photos were taken with the tumour edge at the
middle of the photo, meaning that half of the photo was
tumour and the other half benign tissue outside the
tumour. In that way, hot spots of lymphocytes, often
found around lymphatic vessels just outside the tumour,
were included in the ﬁgures of the tumour border.
Results labelled as ‘‘within the tumour’’ do not include
parts photoed as tumour border. We tried to get 20
photos at the edge and 20 in the interior of the cancers,
but that was often not possible and especially not in the
core biopsies. The median number of photos taken in
the core biopsies was 4 (range 1–10) at the border of the
tumour and 9 (1–36) within the tumour. The number of
photos taken of the vital tumour after ILT was 19 (3–42)
at the edge and 17 (2–46) within. Representative photos
were taken of lymph nodes with and without cancer.
Immunohistological reactions were considered positive
only if the cell nucleus was seen. We recorded the distri-
bution of labelled cells between the cancer nests, the
stroma within the cancer and the benign tissue just outside
the cancer. In the lymph nodes, the visual ﬁeld with the
highest number of positive cells (‘‘hot spot’’) was used for
counting.
The reason for using the ‘‘hot spot’’ method for
counting cells in lymph nodes was the fact that many
visual ﬁelds contained zero or very few positive cells.
Counting of CD4?, CD20?, CD8? and CD68? cells in
lymph nodes was not possible because of the extreme
amount of positive cells. The average number of cells per
visual ﬁeld was reported for core biopsies and for
resected tumours. We used the ‘‘hot spot’’ method also
for the tumour specimens and the results did not differ
(data not shown).
Computerized digital analysis
For computerized digital analysis, pictures were scanned
and captured with a three-colour charge in order to facili-
tate interpretation and quantiﬁcation of ﬁndings [16]. The
images were saved in TIFF (Tagged Image File Format)
format for analysis with Image-Pro Plus 4.5 software
Cancer Immunol Immunother (2011) 60:847–856 849
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was used for counting the cells for all antibodies except
CD68? and CD25? Foxp3? cells. These were marked as
the others but then counted manually. The reason for the
individual counting of CD68? cells was that it enabled us
to exclude CD68? (myo)ﬁbroblasts. A few slender
(myo)ﬁbroblasts were positive in the CD8? reaction but it
was possible to choose a colour span so that the program
could identify only CD8? cells and not (myo)ﬁbroblasts.
CD25? Foxp3? cells were counted individually in order
to be able to discriminate between double-stained CD25?
Foxp3? cells and single-stained CD25? or Foxp3?
lymphocytes.
Image-Pro Plus was also used to calculate the stained
area (lm
2) and the Integrated Optical Density (IOD)
(area 9 average density) for the different colours in the
tumour tissue [16]. Area and IOD calculations conﬁrmed
the cell counting results but did not give any new or dis-
agreeing information (data not shown).
Statistical analysis
Each patient was its own control, that is, we used the dif-
ference in number of cells for the various antibodies
between the core biopsy and the resected tissue. Statistical
signiﬁcance of these differences was determined by the
paired t test, and Student’s t test was used for comparing
ILT patients with the control group. A P-value of \0.05
was considered signiﬁcant.
Results
There was a great variation in the density of immuno-
competent cells between patients and in the tumour spec-
imens from the same patient, both in ILT and control
patients.
CD4? and CD20? cells were mostly found in the
benign breast tissue outside the cancers and occasionally
within the cancer stroma when the stroma was rich or,
occasionally, between benign glandular cells when such
cells were found within the cancers. CD8? cells were
found at the tumour border and also within the tumour,
usually in the stroma between the cancer nests and in some
cases also within the cancer nests (Fig. 1). Other cell types
were mostly found in the stroma between cancer nests and
rarely in the benign tissue at the tumour border.
Counts for the NK cell markers CD57 and, especially,
CD94 were low and showed little variation between
groups. This was also true for granzyme B. As a conse-
quence, data for these cells are not shown. A few cancer
cells were Foxp3? positive (data not shown).
Tumour border
Figure 2 summarizes the ﬁndings at the tumour border and
compares the cell densities before and after laser treatment.
The predominant cell types were CD8?, CD20? and
CD68 ? cells (Fig. 3). Signiﬁcant increases in the resected
tumour after ILT, when compared to the pre-treatment core
biopsies, were observed for CD20? (P\0.05), CD68?
(P\0.001) and CD83? (P\0.01) cells. A few patients
had many CD68? macrophages before ILT and showed no
or little change in number after ILT. This was true also for
CD68? cells within the tumour. There was a tendency for
CD8? cells to be increased after laser treatment
(P = 0.12). The CD8?/CD4? ratio was not signiﬁcantly
increased after ILT when compared to pre-treatment
biopsies (P = 0.20).
There were no signiﬁcant differences between pre- and
postoperative cell counts in control patients receiving sur-
gery only (Table 2). Cell counts in resected specimens in
control (surgery alone) and laser-treated patients were
similar (Fig. 2; Table 2).
Within tumour
Largely, CD8? and CD68? cells were found within the
cancers. The densities of CD8 and CD68 ? cells were
signiﬁcantly larger after ILT than in the pre-treatment
biopsies (Fig. 4; P\0.05 and P\0.01, respectively).
There was no signiﬁcant increase in the CD8?/CD4? ratio
after ILT. The number of CD25? cells tended to be larger
and the number of CD25? Foxp3? cells smaller, after
Fig. 1 Cytotoxic T cells (CD8, brown colour) at the tumour border
(910 objective). Positive cells are seen at the border in the stroma and
also within the cancer nests (exempliﬁed by white arrows). A few
(myo)ﬁbroblasts are also positive (exempliﬁed by black arrows)
850 Cancer Immunol Immunother (2011) 60:847–856
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respectively).
In the control patients, i.e. patients not submitted to ILT,
the number of CD8? cells was larger after than before
surgery (Table 2, P\0.05). Values for CD25?, CD68?,
granzyme B? and CD25? Foxp3? cells were of similar
magnitude before and after surgery (Table 2). CD68?
counts were larger after ILT than after surgery alone
(Fig. 4; Table 2; P\0.05).
Lymph nodes
As a rule, the number of immunocompetent cells in lymph
nodes correlated with the presence or absence of lymph
node metastases. The inﬂuence was obvious for the
lymph nodes containing cancer when compared to lymph
nodes in metastasis-free patients but there was a strong
trend also when comparison was made between metastasis-
free and metastasis-containing lymph nodes in patients
with lymph node metastases (Table 3). In order to try to
ﬁnd possible effects of ILT on these cells, we therefore had
to restrict the comparison between ILT and control patients
to patients without lymph node metastases, in laser-treated
and control patients (Fig. 5). This was done also for
CD25? Foxp3? lymphocytes (Fig. 6), although it may be
mentioned that these cells did not appear to follow the
general pattern and that the presence of cancer in a lymph
node had no, or little, inﬂuence on the number of CD25?
Foxp3? cells (Table 3).
Comparison between ILT ± resection and resection
alone. When compared to surgical resection only, ILT and
resection were followed by a lower number of CD25?
Foxp3? lymphocytes (Fig. 5; P\0.05). Also, in patients
without lymph node metastases, ILT was followed by a
non-signiﬁcant increase in CD1a? (P = 0.15) and a non-
signiﬁcant decrease in CD25? (P = 0.20).
Inﬂuence of lymph node metastasis (laser-treated
patients). Cancer-free lymph nodes in patients with lymph
Fig. 2 Findings at the tumour border. Comparison of cell densities
before and after interstitial laser thermotherapy (ILT). Paired t test:
*P\0.05, **P\0.01, ***P\0.001
Fig. 3 Mature dendritic cells (CD83, brown colour) at the irregular
tumour border to the left (910 objective). Positive cells are seen at the
border in the stroma (arrows)
Table 2 Pre-and postoperative tumour ﬁndings in controls (patients
receiving surgery only) (n = 6)
Tumour border Within tumour
Preoperative Postoperative Preoperative Postoperative
CD8 38.0 ± 16.1 47.1 ± 12.1 17.3 ± 6.2 24.1 ± 7.9*
CD20 18.9 ± 11.4 26.2 ± 7.4 ND ND
CD4 14.1 ± 6.9 19.3 ± 11.5 ND ND
CD25 1.8 ± 0.9 1.0 ± 0.5 0.79 ± 0.40 0.75 ± 0.32
CD68 19.3 ± 5.3 18.6 ± 2.8 11.5 ± 2.3 12.3 ± 2.4
CD83 2.2 ± 0.9 2.5 ± 0.8 ND ND
Granzyme
B
0.40 ± 0.21 0.16 ± 0.04 0.14 ± 0.05 0.05 ± 0.01
CD25
Foxp3
1.9 ± 0.9 0.51 ± 0.16 1.08 ± 0.17 1.15 ± 1.15
ND not done
* P\0.05 for comparison of pre- and postoperative levels
Fig. 4 Cell densities within the tumour before and after interstitial
laser thermotherapy (ILT). Paired t test: *P\0.05
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CD83?, CD25? and granzyme B ? cells as lymph nodes
in metastases-free patients (Fig. 5; Table 3).
Cancer-containing lymph nodes had lower numbers of
CD1a? and CD83? dendritic cells than lymph nodes in
patients without nodal metastases (Table 3; P\0.01 in
both cases). Also, there was a trend towards lower counts
of CD25? (P = 0.11) in cancer-containing lymph nodes
than in lymph nodes in patients without lymph node
metastases.
In patients with lymph node metastases, there were no
signiﬁcant differences between lymph nodes containing
cancer and cancer-free lymph nodes (Table 3). However,
there were strong trends towards decreased counts of
CD1a? (P = 0.06), CD83? (P = 0.06), CD25? (P =
0.09) and granzyme B? cells (P = 0.09) in lymph nodes
containing cancer.
Discussion
Undesirable effects of surgery include shedding of tumour
cells into the circulation and the operative ﬁeld, release of
growth factors and immunosuppression [18]. In breast
cancer, ILT should be of interest because it (a) can ablate a
tumour without causing immunosuppression, (b) can
improve the presentation of tumour antigens—inefﬁcient
antigen presentation limits the immune response to cancer
[23]—which may induce or enhance anti-tumour immunity
and (c) can be used in combination with surgical resection
and immunomodulating drugs.
The microenvironment of cancer has become appreci-
ated as an important factor in cancer immunology. Most
cancers have few immunocompetent cells, and most
tumour-associated antigens are self-antigens and only a
few are tumour speciﬁc [24]. T cells are hypofunctional
and need to be activated for effective immune responses,
for instance, by an acute inﬂammatory reaction induced by
cell death [25, 26]. Changes induced by ILT may have
positive effects on tumour immunogenicity not only by
providing a source of tumour antigens but also by pro-
ducing changes in the microenvironment.
In the present study, there was a large variation in the
density of immunocompetent cells, both between patients
and between different tumour areas within the same
patient. We used intraindividual paired comparisons to deal
with the variation between individuals and computerized
digital analysis to diminish the effect of variations within
the same tumour. Nevertheless, it should be pointed out
Table 3 Immunocompetent cells in regional lymph nodes—inﬂuence of lymph node metastases in laser-treated patients
CD1a CD83 CD25 CD25 Foxp3 Granzyme B
I. Patients without lymph node metastases 63.8 ± 13.7 37.7 ± 7.4 41.7 ± 9.0 15.1 ± 3.8 20.1 ± 8.6
II. Patients with lymph node metastases-lymph nodes with tumour 3.8 ± 0.5 4.6 ± 2.9 17.8 ± 7.4 14.7 ± 5.0 6.1 ± 3.3
Comparison with (I) metastases-free patients (P) \0.01 \0.01 0.11 0.94 0.26
III. Patients with lymph node metastases-lymph nodes without tumour 48.3 ± 20.8 43.4 ± 19.0 43.2 ± 11.5 7.3 ± 2.4 19.1 ± 6.2
Comparison with (II) tumour-free nodes in patients with metastases (P) 0.06 0.06 0.09 0.22 0.09
Fig. 5 Comparison of cell densities in regional lymph nodes after
interstitial laser thermotherapy (ILT) and in controls (surgical
resection only). Data after ILT represent ﬁndings in metastasis-free
lymph nodes. Statistical comparison between ILT and controls was
performed using only metastasis-free lymph nodes due to the
inﬂuence of metastatic growth (Table 3). Students’ t test: *P\0.05
Fig. 6 CD25?/Foxp3? cells (CD25? red colour, Foxp3? brown
colour) (exempliﬁed by arrows) in a lymph node (209 objective).
Cells stained red only represent CD25? lymphocytes
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carries the risk of obtaining falsely positive ﬁndings.
The number of immune inﬁltrating cells before treat-
ment at the tumour border in the laser-treated patients and
in the control patients was similar, as seen by comparing
data in Figs. 2 and 4 (laser-treated patients) with data in
Table 2 (control patients). Thus, it does not appear that
difﬁculty to visualize the tumour border on ultrasound
indicated a factor correlating with the number of immune
inﬁltrating cells.
Mature and immature dendritic cells (CD83?
and CD1a? cells)
Dendritic cells are important antigen-presenting cells
(APCs) whose role is to capture and process antigen via the
MHC-II pathway for presentation to CD4? T cells. Den-
dritic cells are present in very low numbers in normal
breast tissue and their presence in malignant breast tumours
is associated with improved prognosis [27–29]. Bell et al.
[27] described that immature dendritic cells (CD1a?) are
found within the tumour and that mature dendritic cells
(CD83?) are present at the tumour border and suggested
that this reﬂects an ongoing immune response.
In the present study, there was no signiﬁcant difference
in the number of CD1a? cells after ILT within the tumour
or at the tumour border. Mature dendritic cells (CD83?)
were signiﬁcantly increased at the tumour border after ILT
(Figs. 2, 3). An increased number of CD83? cells at the
tumour border have been reported to be a positive prog-
nostic factor both in breast cancer [29] and metastatic liver
tumours from colorectal cancer [30]. We have shown [16]
that ILT induces increased expression of HSP70 in tumour
cells and this seems to be a likely explanation for the
induction of mature CD83? dendritic cells after ILT [31].
In the lymph nodes, there was a trend towards an
increased number of CD1a? cells after ILT in patients
without lymph node metastases (Fig. 5; P = 0.15). Lymph
nodes with cancer had low counts of CD1a? and CD83?
(Table 3), both when compared to lymph nodes in patients
without lymph node metastases (P\0.01 in both cases)
and when compared to negative lymph nodes in patients
with positive nodes (P = 0.06 in both cases). The results
for CD83? agree with those of Poindexter et al., who
found a trend towards lower numbers of CD83? in sentinel
nodes with cancer than in tumour-free sentinel nodes [32].
Macrophages
Macrophages have dual roles [33]. M1 macrophages can
phagocytize tumour cells and produce cytokines, such as
prostaglandins and tumour necrosis factor-alpha (TNFa),
which may stimulate other potent immunological cells. M1
macrophages can also present tumour antigens to cytotoxic
T cells. These factors favour an immunological response to
tumour. M2 macrophages contribute to tumour progression
by secretion of pro-angiogenic and anti-inﬂammatory
mediators and growth factors and can suppress the anti-
tumour immune response [34, 35]. These macrophages
assist tumour progression [36]. Increased inﬁltration of
tumour-associated M2 macrophages (TAMs) has been
described as an indicator of poor prognosis in many
malignant diseases [37].
ILT resulted in signiﬁcantly increased numbers of
macrophages within the tumour and at the tumour border.
The macrophages in the core biopsies are probably both
M1 and M2 subtypes, and our data do not allow any con-
clusion about the net effect of the anti-tumour and tumour
progression activities following ILT [33]. Mantovani et al.
suggested that the balance might be shifted towards anti-
tumour activity if an acute inﬂammatory response is cre-
ated [25]. Such an acute response is generated by ILT,
which produces necrosis rather than apoptosis, and leakage
of intracellular material, resulting in an inﬂammatory
stimulus. It was recently reported that tumour cell death,
induced by chemotherapy or radiotherapy, can activate
tumour antigen presentation via antigen-presenting cells
(APCs), resulting in increased treatment efﬁcacy [38].
T lymphocytes
In our study, there were signiﬁcantly more CD8? T cells
within the resected tumour after ILT than before treatment
(P\0.05) and there was a similar trend towards a higher
number at the tumour border (P = 0.12). The CD8?
lymphocytes were seen within the tumour stroma and in
some cases also within the tumour nests (Fig. 1). Intraep-
ithelial inﬁltrates of CD8? lymphocytes have been corre-
lated with improved prognosis in several malignancies
such as ovarian [39], cervical [40] and colorectal [41]
cancer. A low CD8?/CD4? ratio has been suggested to
worsen prognosis in patients with cervical cancer [42]. In
the present study, there was a tendency towards higher
CD8?/CD4? ratios after ILT.
The ﬁnding of positive (myo)ﬁbroblasts in the CD8
reaction is important. These cells are slender, while lym-
phocytes are round, and therefore easy to recognize in the
microscope and delete from the counting of round
lymphocytes.
Regulatory T cells (Treg cells)
There is substantial evidence that regulatory T cells (Treg
cells) inhibit local anti-tumour immunity and that Treg cells
mediate antigen-speciﬁc local suppression [43]. There are
several subsets of Treg cells, and strong suppressive
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cells identiﬁed in human cancers belong to the CD4?
CD25? Foxp3? population. We studied the presence of
CD25? Foxp3? cells, which left CD4?CD25-Foxp3?
cells undetected but included the majority of regulatory T
cells [44].
Treg cells have been shown to inﬁltrate a number of
cancers and metastatic lymph nodes, including breast [45,
46], ovarian [39, 47], cervical [42] and colorectal cancers
[48, 49], and increase in Treg cells has been shown to
correlate with worse prognosis. Two groups have demon-
strated that a high CD8?/Foxp3? ratio in the primary
tumour seems to overcome the negative effects of regula-
tory T cells in ovarian [47] and cervical [42] cancer.
After ILT, the number of Tregs within the resected tumour
or at the tumour border did not change signiﬁcantly,
althoughtherewasatrendtowardsadecreaseinCD25?and
CD25?Foxp3?cells. However,in the lymphnodes without
metastases, the ILT patients had a signiﬁcantly lower
number of CD25?Foxp3? lymphocytes than the control
patients (Fig. 5). This may indicate a favourable effect of
ILT. It is interesting that Nakamura et al. [46] recently
showed that elevated levels of Tregs in sentinel lymph nodes
predict poor prognosis in node-negative breast cancer.
The reason for the increased density of CD20? cells at
the tumour border after ILT is unclear. The lowered pres-
ence of Treg cells may play a role since it has been shown
that Treg cells can lyse antigen-presenting B cells [50].
Conclusions
Studies of gene expression proﬁles have demonstrated that
there are several breast cancer subtypes with different
behaviour, different prognosis and, probably, different
immunological actions. It has, for instance, been shown
that ‘‘triple negative’’ (ER-, PR-, HER2-) cancers, espe-
cially in combination with high grade, show features of
immune tolerance, as indicated by increased inﬁltration of
Treg cells in the tumour [51]. This and similar ﬁndings [52]
highlight the importance of looking for molecular subtypes
in breast cancer when exploring immunological effects of
treatment.
In our study, the number of patients was low, and only
two ILT patients were both ER- and PR-negative, which
precluded evaluation of the role of different subtypes. Yet,
ILT induced changes in immunocompetent cells in patients
with breast cancer. ILT was followed by increases in
CD8? cytotoxic lymphocytes and mature CD83? den-
dritic cells at the primary tumour and a decrease in
CD25?Foxp3? Treg lymphocytes in regional lymph nodes.
Further work will help to clarify the role of ILT in breast
cancer therapy.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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